Table 2.
Echocardiographic (ECHO) measurements for untreated and treated ZDF (fa/fa) rats
| ZDF |
ZDF+Metformin |
ZDF+Rosiglitazone |
||||
|---|---|---|---|---|---|---|
| W13 (n=6) | Δ (v=4) | W13 (n=6) | Δ (v=6) | W13 (n=6) | Δ (n=6) | |
| LVIDd (mm) | 9.16±0.32 | 0.15±0.29 | 9.13±0.16 | 0.32±0.42 | 8.98±0.13 | 0.93±0.47*,† |
| LVIDs (mm) | 5.53±0.29 | 0.01±0.14 | 5.78±0.39 | 0.19±0.50 | 5.25±0.48 | 0.44±0.96 |
| LVM (g) | 1.00±0.07 | 0.05±0.16 | 1.17±0.10 | 0.38±0.15* | 1.05±0.07 | 0.42±0.08* |
| LVMI | 3.15±0.17 | −0.11±0.47 | 3.61±0.57 | 0.70±0.76*,‡ | 3.21±0.28 | −0.32±0.28 |
| FS (%) | 39.72±1.72 | 0.89±1.30 | 36.70±4.41 | 0.11±5.24 | 41.60±5.44 | 1.19±7.59 |
Average baseline (W13) and change from baseline (Δ).
Values and Values are represented as mean ± 1 standard deviation
*
Treatment response significantly higher than no treatment
†
Treatment response significantly higher than Metformin treatment
‡
Treatment response significantly higher than Rosiglitazone treatment
P-value P<0.05 was considered significant
LVIDd, LV diastolic internal diameter; LVIDs, LV systolic internal diameter; LVM, LV mass; LVMI, LV mass index; FS, fractional shortening